Mendus : Interim Report January - March 2024
English Swedish ...
Source: marketscreener.com
Lotta Ferm News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lotta Ferm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lotta Ferm Today - Breaking & Trending Today
Mendus will participate in multiple investor and industry conferences in October and announces presentation of ALISON trial update at SITC
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: LSX...
Source: marketscreener.com
Mendus to participate in multiple investor and industry conferences in September
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: H.C. Wainwright 25th Annual Global Investment Conference New York, USA, September 11-13, 2023 Mendus CEO Erik Manting will participate and present a Company Update at the conference: https://hcwevents.com/annualconference/ Pareto Securities' Annual Healthcare Conference Stockholm, Swe
Source: yahoo.com
Mendus AB: Mendus secures second shareholder loan from Van Herk Investments and reduces the number of outstanding convertible bonds with Negma Group
07.03.2023 - Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company has closed a second loan under the terms of the commitment from its largest shareholder Van Herk ...
Source: wallstreet-online.de
Correction: Immunicum AB: Immunicum AB (publ) Announces Q4 and Year-End Results 2021
OCTOBER-DECEMBER IN SUMMARY Net sales for the period amounted to KSEK - (-).Result for the period amounted to KSEK -32,844 (-47,880).Earnings and diluted earnings per share totaled SEK -0.16 (-0.58).Immunicum
Source: finanznachrichten.de